EICHORPublic-registry site landscape for NCT07673744, “A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)”, a Myasthenia Gravis study sponsored by TG Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07673744 (registry record) |
| Study title | A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) |
| Official title | A Phase 2, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Treatment Following Induction With Efgartigimod Administration in Adults With Myasthenia Gravis |
| Sponsor | TG Therapeutics, Inc. |
| Condition(s) | Myasthenia Gravis |
| Phase | PHASE2 |
| Listed sites | 2 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT07673744.
Eichor generates a preliminary site-risk snapshot for NCT07673744 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Myasthenia Gravis trials
More from TG Therapeutics, Inc.
← Eichor home · All tracked trials · Myasthenia Gravis studies · Weekly briefs
